ClinicalTrials.gg
CompletedNCT03571256ARTISTS2Updated Nov 9, 2021Results posted

A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)

A Phase 3 interventional study of TEV-50717 and Placebo in Tourette Syndrome, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 56 sites in 10 countries. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
6 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Enrollment
11th of 105
158 · median 33
Started
2018
with 11 others
Phase 3
10 of 139
none open now
Registered
89th of 139
by date

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 11th largest by enrollment of the 105 interventional ones that give a count, is one of 12 that started in 2018, is one of 10 in phase 3, and was the 89th registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

Standard placebo-controlled, double-blind study design (TEV-50717 [low dose and high dose] vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in a statistically significant effect on the tics in participants with TS.

03

Conditions studied

  • Tourette Syndrome

Browse trials for

04

Who can participate

Ages eligible
6 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant weighs at least 44 pounds (20 kg) at baseline.
  • Participant meets the , Fifth Edition (DSM-5™) diagnostic criteria for TS and, in the opinion of the investigator, participant, and parent/legal guardian, the participant's active tics are causing distress or impairment.
  • Participant has a TTS of 20 or higher on the YGTSS at screening and baseline.
  • Participant is able to swallow study medication whole.
  • -Additional criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • Participant has a neurologic disorder other than TS that could obscure the evaluation of tics.
  • The participant 's predominant movement disorder is stereotypy (coordinated movements that repeat continually and identically) associated with autism spectrum disorder.
  • Participant has depression at screening or baseline.
  • Participant has a history of suicidal intent or related behaviors within 2 years of screening
  • Participant has a history of a previous actual, interrupted, or aborted suicide attempt.
  • Participant has a first-degree relative who has completed suicide.
  • Participant has a confirmed diagnosis of bipolar disorder, schizophrenia, or another psychotic disorder.
  • Participant has received Comprehensive Behavioral Intervention for Tics for TS or Cognitive Behavioral Therapy for obsessive-compulsive disorder (OCD) within 4 weeks of screening.
  • Participant has received treatment with deep brain stimulation, transmagnetic stimulation, or transcranial direct current stimulation within 4 weeks of the screening visit for reduction of tics.
  • Participant has a history of torsades de pointes, congenital long syndrome, bradyarrhythmias, or uncompensated heart failure.
  • Participant has participated in an drug or device study and received investigational medicinal product (IMP)/intervention within 30 days or 5 drug half-lives of baseline, whichever is longer.
  • Participant is a pregnant or lactating female, or plans to be pregnant during the study.
  • -Additional criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    TEV-50717 High-Dose

    TEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 8 weeks

    Drug: TEV-50717 · Drug: Placebo

  • Experimental
    TEV-50717 Low-Dose

    TEV-50717 tablets BID up to 36 mg/day orally for a total of 8 weeks

    Drug: TEV-50717 · Drug: Placebo

  • Placebo comparator
    Placebo

    Placebo matched to TEV-50717 for a total of 8 weeks

    Drug: Placebo

Interventions

  • DrugTEV-50717

    6-, 9-, 12-, 15-, and 18 mg oral tablets

    Also known as: AUSTEDO, Deutetrabenazine

  • DrugPlacebo

    Placebo matched to TEV-50717 tablets will be taken BID.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the TTS of the YGTSS at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    YGTSS rating scale is a semi-structured clinician rating instrument that provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic tics. YGTSS is composed of 11 items: 5 items for motor tic severity, 5 items for vocal tic severity, and 1 item for impairment. Each item for motor tic severity and vocal is rated on a 6-point scale (0 for none to 5 to severe). MTSS is the sum of the 5 items for motor tic severity and VTSS is the sum of the 5 items for vocal tic severity. TTS is the sum of MTSS and VTSS, ranges from 0 (none/absent) to 50 (severe). Higher scores indicate greater severity/worse outcome. Least square (LS) mean and standard error (SE) was calculated using mixed-model repeated-measures (MMRM) with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Change From Baseline in the Tourette Syndrome-Clinical Global Impression (TS-CGI) Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    The TS-CGI scale is a 7-point Likert scale that allows the clinician to use all available information to assess the impact of tics on the participant's quality of life. The TS-CGI is rated as follows: 1 (normal or no tics at all), 2 (borderline), 3 (mild), 4 (moderate), 5 (marked), 6 (severe), and 7 (extreme, incapacitating tics). Lower scores indicate better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.

    Time frame: Baseline, Week 8

  2. Change From Baseline in the TTS of the YGTSS at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    YGTSS rating scale is a semi-structured clinician rating instrument that provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic tics. YGTSS is composed of 11 items: 5 items for motor tic severity, 5 items for vocal tic severity, and 1 item for impairment. Each item for motor tic severity and vocal is rated on a 6-point scale (0 for none to 5 to severe). MTSS is the sum of the 5 items for motor tic severity and VTSS is the sum of the 5 items for vocal tic severity. TTS is the sum of MTSS and VTSS, ranges from 0 (none/absent) to 50 (severe). Higher scores indicate greater severity/worse outcome. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.

    Time frame: Baseline, Week 8

  3. Change From Baseline in the TS-CGI Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    The TS-CGI scale is a 7-point Likert scale that allows the clinician to use all available information to assess the impact of tics on the participant's quality of life. The TS-CGI is rated as follows: 1 (normal or no tics at all), 2 (borderline), 3 (mild), 4 (moderate), 5 (marked), 6 (severe), and 7 (extreme, incapacitating tics). Lower scores indicate better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.

    Time frame: Baseline, Week 8

  4. Change From Baseline in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    The TS-PGII is a single-item questionnaire that asks the participant to assess the degree of impact due to current tics (How much do your current tics disrupt things in your life?). The TS-PGII uses a 5-point scale, ranging from not at all (1) to very much (5), to assess overall response to therapy.

    Time frame: Baseline, Week 8

  5. Change From Baseline in the TS-PGII Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    The TS-PGII is a single-item questionnaire that asks the participant to assess the degree of impact due to current tics (How much do your current tics disrupt things in your life?). The TS-PGII uses a 5-point scale, ranging from not at all (1) to very much (5), to assess overall response to therapy.

    Time frame: Baseline, Week 8

  6. Change From Baseline in the Child and Adolescent Gilles de la Tourette Syndrome - Quality of Life (C&A-GTS-QOL) Activities of Daily Living (ADL) Subscale Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    C\&A-GTS-QOL is a 27-item questionnaire that asks participant to assess the extent to which their quality of life is impacted by their symptoms. C\&A-GTS-QOL contains 6 subscales (cognitive, coprophenomena, psychological, physical, obsessive-compulsive, and ADL) and uses a 5-point Likert scale ranging from no problem to extreme problem. Following 3 questions from 27-item questionnaire were assessed in ADL C\&A-GTS-QOL subscale: Question 2 (Had difficulty with school or sport activities?), 24 (Felt you needed more help or support from other people?), and 26 (Had difficulty going out with other people?). Total score of ADL subscale ranged from 0 (no problem) to 12 (extreme problem). Lower score indicated better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6-11 years, 12-16 years) as covariates.

    Time frame: Baseline, Week 8

  7. Change From Baseline in the C&A-GTS-QOL ADL Subscale Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    C\&A-GTS-QOL is a 27-item questionnaire that asks participant to assess the extent to which their quality of life is impacted by their symptoms. C\&A-GTS-QOL contains 6 subscales (cognitive, coprophenomena, psychological, physical, obsessive-compulsive, and ADL) and uses a 5-point Likert scale ranging from no problem to extreme problem. Following 3 questions from 27-item questionnaire were assessed in ADL C\&A-GTS-QOL subscale: Question 2 (Had difficulty with school or sport activities?), 24 (Felt you needed more help or support from other people?), and 26 (Had difficulty going out with other people?). Total score of ADL subscale ranged from 0 (no problem) to 12 (extreme problem). Lower score indicated better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6-11 years, 12-16 years) as covariates.

    Time frame: Baseline, Week 8

  8. Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version and Self-reported Version) Total Score at Week 9

    CDI-2 self-report: 28-item questionnaire assessing depressive symptoms in children 7 to 17 years of age with basic reading and comprehension skills. Children were asked to choose 1 of 3 statements that most closely aligns with their feelings in past 2 weeks. It contains 6 subscales (emotional problem, negative mood/physical symptoms, negative self-esteem, functional problems, ineffectiveness, interpersonal problems). Total score: sum of all subscales scores, ranging from 0 to 56, with higher score indicating greater depression severity.CDI-2 parent: 17-item questionnaire administered to parents to assess depression-related behaviors observed in their children. Parents were asked to rate their child's behaviors in past 2 weeks on a 4-point Likert scale from "not at all" to "much or most of the time." It contains 2 subscales (emotional problems and functional problem). Total score: sum of 2 subscales, ranging from 0 to 51, with higher score indicating more depression-related behaviors.

    Time frame: Baseline, Week 9

  9. Number of Participants at Baseline and Week 9 With Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS)

    C-SSRS included responses for Suicidal Ideation or Suicidal Behavior in following 10 categories: 1 = Wish to be dead; 2 = Non-specific active suicidal thoughts; 3 = Active suicidal ideation with any methods (not plan) without intent to act; 4 = Active suicidal ideation with some intent to act, without specific plan; 5 = Active suicidal ideation with specific plan and intent; 6 = Preparatory acts or behavior; 7 = Aborted attempt; 8 = Interrupted attempt; 9 = Non-fatal suicide attempt; and 10 = Completed suicide. Number of participants with any suicidal ideation or suicidal behavior are reported. Any Suicidal ideation or Suicidal Behavior events reported as TEAEs along with all other reported TEAEs are included in the AE module.

    Time frame: Baseline, Week 9

07

Results

Posted Jun 9, 2020

Participant flow

Participant flow — Overall Study
MilestoneTEV-50717 High-DoseTEV-50717 Low-DosePlacebo
Started525452
Safety analysis set525451
Modified itt (mitt) analysis set495351
Completed465148
Not completed634
Withdrew: Adverse event301
Withdrew: Withdrawal by subject311
Withdrew: Other than specified011
Withdrew: Protocol violation011

Outcome measures

PrimaryChange From Baseline in the TTS of the YGTSS at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

YGTSS rating scale is a semi-structured clinician rating instrument that provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic tics. YGTSS is composed of 11 items: 5 items for motor tic severity, 5 items for vocal tic severity, and 1 item for impairment. Each item for motor tic severity and vocal is rated on a 6-point scale (0 for none to 5 to severe). MTSS is the sum of the 5 items for motor tic severity and VTSS is the sum of the 5 items for vocal tic severity. TTS is the sum of MTSS and VTSS, ranges from 0 (none/absent) to 50 (severe). Higher scores indicate greater severity/worse outcome. Least square (LS) mean and standard error (SE) was calculated using mixed-model repeated-measures (MMRM) with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · units on a scale
Change From Baseline in the TTS of the YGTSS at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
units on a scaleTEV-50717 High-DosePlacebo
Change From Baseline in the TTS of the YGTSS at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants-7.8 ± 1.24-7.0 ± 1.16
Statistical analysis
  • TEV-50717 High-Dose vs Placebo · Mixed Models Analysis · p = 0.600 (Threshold for significance at 0.05 level.) · Ls mean difference: -0.8 · 95% CI -3.9 to 2.3
SecondaryChange From Baseline in the Tourette Syndrome-Clinical Global Impression (TS-CGI) Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

The TS-CGI scale is a 7-point Likert scale that allows the clinician to use all available information to assess the impact of tics on the participant's quality of life. The TS-CGI is rated as follows: 1 (normal or no tics at all), 2 (borderline), 3 (mild), 4 (moderate), 5 (marked), 6 (severe), and 7 (extreme, incapacitating tics). Lower scores indicate better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Tourette Syndrome-Clinical Global Impression (TS-CGI) Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
units on a scaleTEV-50717 High-DosePlacebo
Change From Baseline in the Tourette Syndrome-Clinical Global Impression (TS-CGI) Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants-0.8 ± 0.14-0.6 ± 0.13
SecondaryChange From Baseline in the TTS of the YGTSS at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

YGTSS rating scale is a semi-structured clinician rating instrument that provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic tics. YGTSS is composed of 11 items: 5 items for motor tic severity, 5 items for vocal tic severity, and 1 item for impairment. Each item for motor tic severity and vocal is rated on a 6-point scale (0 for none to 5 to severe). MTSS is the sum of the 5 items for motor tic severity and VTSS is the sum of the 5 items for vocal tic severity. TTS is the sum of MTSS and VTSS, ranges from 0 (none/absent) to 50 (severe). Higher scores indicate greater severity/worse outcome. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · units on a scale
Change From Baseline in the TTS of the YGTSS at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
units on a scaleTEV-50717 Low-DosePlacebo
Change From Baseline in the TTS of the YGTSS at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants-5.9 ± 1.18-7.0 ± 1.16
SecondaryChange From Baseline in the TS-CGI Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

The TS-CGI scale is a 7-point Likert scale that allows the clinician to use all available information to assess the impact of tics on the participant's quality of life. The TS-CGI is rated as follows: 1 (normal or no tics at all), 2 (borderline), 3 (mild), 4 (moderate), 5 (marked), 6 (severe), and 7 (extreme, incapacitating tics). Lower scores indicate better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · units on a scale
Change From Baseline in the TS-CGI Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
units on a scaleTEV-50717 Low-DosePlacebo
Change From Baseline in the TS-CGI Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants-0.6 ± 0.13-0.6 ± 0.13
SecondaryChange From Baseline in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

The TS-PGII is a single-item questionnaire that asks the participant to assess the degree of impact due to current tics (How much do your current tics disrupt things in your life?). The TS-PGII uses a 5-point scale, ranging from not at all (1) to very much (5), to assess overall response to therapy.

Time frame:
Baseline, Week 8
Reported as:
Mean · units on a scale
Change From Baseline in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
units on a scaleTEV-50717 High-DosePlacebo
Change From Baseline in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants-0.8 ± 0.17-0.7 ± 0.16
SecondaryChange From Baseline in the TS-PGII Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

The TS-PGII is a single-item questionnaire that asks the participant to assess the degree of impact due to current tics (How much do your current tics disrupt things in your life?). The TS-PGII uses a 5-point scale, ranging from not at all (1) to very much (5), to assess overall response to therapy.

Time frame:
Baseline, Week 8
Reported as:
Mean · units on a scale
Change From Baseline in the TS-PGII Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
units on a scaleTEV-50717 Low-DosePlacebo
Change From Baseline in the TS-PGII Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants-0.7 ± 0.15-0.7 ± 0.16
SecondaryChange From Baseline in the Child and Adolescent Gilles de la Tourette Syndrome - Quality of Life (C&A-GTS-QOL) Activities of Daily Living (ADL) Subscale Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

C\&A-GTS-QOL is a 27-item questionnaire that asks participant to assess the extent to which their quality of life is impacted by their symptoms. C\&A-GTS-QOL contains 6 subscales (cognitive, coprophenomena, psychological, physical, obsessive-compulsive, and ADL) and uses a 5-point Likert scale ranging from no problem to extreme problem. Following 3 questions from 27-item questionnaire were assessed in ADL C\&A-GTS-QOL subscale: Question 2 (Had difficulty with school or sport activities?), 24 (Felt you needed more help or support from other people?), and 26 (Had difficulty going out with other people?). Total score of ADL subscale ranged from 0 (no problem) to 12 (extreme problem). Lower score indicated better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6-11 years, 12-16 years) as covariates.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Child and Adolescent Gilles de la Tourette Syndrome - Quality of Life (C&A-GTS-QOL) Activities of Daily Living (ADL) Subscale Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
units on a scaleTEV-50717 High-DosePlacebo
Change From Baseline in the Child and Adolescent Gilles de la Tourette Syndrome - Quality of Life (C&A-GTS-QOL) Activities of Daily Living (ADL) Subscale Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants-10.3 ± 2.85-9.0 ± 2.66
SecondaryChange From Baseline in the C&A-GTS-QOL ADL Subscale Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

C\&A-GTS-QOL is a 27-item questionnaire that asks participant to assess the extent to which their quality of life is impacted by their symptoms. C\&A-GTS-QOL contains 6 subscales (cognitive, coprophenomena, psychological, physical, obsessive-compulsive, and ADL) and uses a 5-point Likert scale ranging from no problem to extreme problem. Following 3 questions from 27-item questionnaire were assessed in ADL C\&A-GTS-QOL subscale: Question 2 (Had difficulty with school or sport activities?), 24 (Felt you needed more help or support from other people?), and 26 (Had difficulty going out with other people?). Total score of ADL subscale ranged from 0 (no problem) to 12 (extreme problem). Lower score indicated better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6-11 years, 12-16 years) as covariates.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · units on a scale
Change From Baseline in the C&A-GTS-QOL ADL Subscale Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
units on a scaleTEV-50717 Low-DosePlacebo
Change From Baseline in the C&A-GTS-QOL ADL Subscale Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants-10.0 ± 2.68-9.0 ± 2.66
SecondaryChange From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version and Self-reported Version) Total Score at Week 9

CDI-2 self-report: 28-item questionnaire assessing depressive symptoms in children 7 to 17 years of age with basic reading and comprehension skills. Children were asked to choose 1 of 3 statements that most closely aligns with their feelings in past 2 weeks. It contains 6 subscales (emotional problem, negative mood/physical symptoms, negative self-esteem, functional problems, ineffectiveness, interpersonal problems). Total score: sum of all subscales scores, ranging from 0 to 56, with higher score indicating greater depression severity.CDI-2 parent: 17-item questionnaire administered to parents to assess depression-related behaviors observed in their children. Parents were asked to rate their child's behaviors in past 2 weeks on a 4-point Likert scale from "not at all" to "much or most of the time." It contains 2 subscales (emotional problems and functional problem). Total score: sum of 2 subscales, ranging from 0 to 51, with higher score indicating more depression-related behaviors.

Time frame:
Baseline, Week 9
Reported as:
Mean · units on a scale
Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version and Self-reported Version) Total Score at Week 9
units on a scaleTEV-50717 High-DoseTEV-50717 Low-DosePlacebo
CDI-2 Parent Version-1.2 ± 6.53-3.8 ± 6.34-0.8 ± 5.36
CDI-2 Self-Reported Version-2.0 ± 4.13-2.6 ± 4.90-0.4 ± 4.99
SecondaryNumber of Participants at Baseline and Week 9 With Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS)

C-SSRS included responses for Suicidal Ideation or Suicidal Behavior in following 10 categories: 1 = Wish to be dead; 2 = Non-specific active suicidal thoughts; 3 = Active suicidal ideation with any methods (not plan) without intent to act; 4 = Active suicidal ideation with some intent to act, without specific plan; 5 = Active suicidal ideation with specific plan and intent; 6 = Preparatory acts or behavior; 7 = Aborted attempt; 8 = Interrupted attempt; 9 = Non-fatal suicide attempt; and 10 = Completed suicide. Number of participants with any suicidal ideation or suicidal behavior are reported. Any Suicidal ideation or Suicidal Behavior events reported as TEAEs along with all other reported TEAEs are included in the AE module.

Time frame:
Baseline, Week 9
Reported as:
Count of participants · Participants
Number of Participants at Baseline and Week 9 With Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsTEV-50717 High-DoseTEV-50717 Low-DosePlacebo
Baseline002
Week 9000

Adverse events

Collected over Baseline (Day 1) to follow-up (Week 10). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TEV-50717 High-Dose0/52 (0%)1/52 (1.9%)19/52 (36.5%)
TEV-50717 Low-Dose0/54 (0%)0/54 (0%)16/54 (29.6%)
Placebo0/51 (0%)0/51 (0%)12/51 (23.5%)
Most frequent serious events
Most frequent serious events
EventTEV-50717 High-DoseTEV-50717 Low-DosePlacebo
Attention deficit/hyperactivity disorderPsychiatric disorders1/520/540/51
TicPsychiatric disorders1/520/540/51
Most frequent other events
Most frequent other events
EventTEV-50717 High-DoseTEV-50717 Low-DosePlacebo
SomnolenceNervous system disorders8/522/541/51
HeadacheNervous system disorders6/528/544/51
NasopharyngitisInfections and infestations6/522/543/51
FatigueGeneral disorders5/521/540/51
VomitingGastrointestinal disorders3/521/544/51
Increased appetiteMetabolism and nutrition disorders4/521/540/51
Pain in extremityMusculoskeletal and connective tissue disorders2/520/543/51
NauseaGastrointestinal disorders2/523/540/51

Baseline characteristics

ITT analysis set included all randomized participants.

Age, Continuous
Age, Continuous(years)TEV-50717 High-DoseTEV-50717 Low-DosePlaceboTotal
Mean11.7 ± 2.6311.7 ± 2.7011.8 ± 2.6211.7 ± 2.64
Sex: Female, Male
Sex: Female, Male(Participants)TEV-50717 High-DoseTEV-50717 Low-DosePlaceboTotal
Female15121239
Male374240119
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TEV-50717 High-DoseTEV-50717 Low-DosePlaceboTotal
Hispanic or Latino891532
Not Hispanic or Latino434537125
Unknown or Not Reported1001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TEV-50717 High-DoseTEV-50717 Low-DosePlaceboTotal
White484839135
Black0101
Asian0347
Native American1124
Multiple0022
Other3159
Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)
Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)(units on a scale)TEV-50717 High-DoseTEV-50717 Low-DosePlaceboTotal
Mean33.9 ± 6.1732.9 ± 7.2034.7 ± 6.2933.8 ± 6.58
08

Study locations

56 sites
  • Teva Investigational Site 060-0160
    Gainesville, Florida 32608, United States
  • Teva Investigational Site 060-0166
    Gulf Breeze, Florida 32561-4458, United States
  • Teva Investigational Site 060-0161
    Miami, Florida 33136-2107, United States
  • Teva Investigational Site 060-0151
    Orlando, Florida 32801, United States
  • Teva Investigational Site 060-0153
    Orlando, Florida 32819, United States
  • Teva Investigational Site 060-0168
    Atlanta, Georgia 30329, United States
  • Teva Investigational Site 060-0155
    Chicago, Illinois 60612, United States
  • Teva Investigational Site 060-0164
    Chicago, Illinois 60634, United States
  • Teva Investigational Site 060-0152
    Indianapolis, Indiana 46256, United States
  • Teva Investigational Site 060-0158
    Louisville, Kentucky 40202, United States
  • Teva Investigational Site 060-0167
    Rockville, Maryland 20852-4219, United States
  • Teva Investigational Site 060-0165
    Ann Arbor, Michigan 48105, United States
  • Teva Investigational Site 060-0170
    Bridgeton, Missouri 63044, United States
  • Teva Investigational Site 060-0154
    New York, New York 10036, United States
  • Teva Investigational Site 060-0169
    Charleston, South Carolina 29414-5834, United States
  • Teva Investigational Site 060-0157
    Memphis, Tennessee 38157, United States
  • Teva Investigational Site 060-0156
    Nashville, Tennessee 37232-2551, United States
  • Teva Investigational Site 060-0163
    Fort Worth, Texas 76104, United States
  • Teva Investigational Site 060-0162
    Everett, Washington 98201-4077, United States
  • Teva Investigational Site 060-1407
    Buenos Aires, C1023AAB, Argentina
  • Teva Investigational Site 060-1401
    Buenos Aires, C1058AAJ, Argentina
  • Teva Investigational Site 060-1402
    Buenos Aires, C1425AHQ, Argentina
  • Teva Investigational Site 060-1403
    La Plata, 1900, Argentina
  • Teva Investigational Site 060-1404
    Mendoza, 5500, Argentina
  • Teva Investigational Site 060-1802
    Liverpool, 2170, Australia
  • Teva Investigational Site 060-1801
    Parkville, 3052, Australia
  • Teva Investigational Site 060-1503
    Bello, 051050, Colombia
  • Teva Investigational Site 060-1501
    Medellin, 5500515, Colombia
  • Teva Investigational Site 060-1506
    Medellin, 78 B 50, Colombia
  • Teva Investigational Site 060-1504
    Pereira, 660003, Colombia
  • Teva Investigational Site 060-0901
    Budapest, 1021, Hungary
  • Teva Investigational Site 060-0902
    Szeged, 6725, Hungary
  • Teva Investigational Site 060-1005
    Cagliari, 09121, Italy
  • Teva Investigational Site 060-1001
    Catania, 95123, Italy
  • Teva Investigational Site 060-1003
    Naples, 80131, Italy
  • Teva Investigational Site 060-1004
    Rome, 00165, Italy
  • Teva Investigational Site 060-1901
    Seoul, 110-744, Korea, Republic of
  • Teva Investigational Site 060-1903
    Seoul, 138-736, Korea, Republic of
  • Teva Investigational Site 060-1904
    Seoul, 3722, Korea, Republic of
  • Teva Investigational Site 060-1902
    Seoul, 6351, Korea, Republic of
  • Teva Investigational Site 060-1601
    Culiacan, 80020, Mexico
  • Teva Investigational Site 060-1603
    Leon, 37000, Mexico
  • Teva Investigational Site 060-1602
    Monterrey, 64460, Mexico
  • Teva Investigational Site 060-1604
    Monterrey, 64610, Mexico
  • Teva Investigational Site 060-1104
    Gdansk, 80-542, Poland
  • Teva Investigational Site 060-1101
    Katowice, 40-123, Poland
  • Teva Investigational Site 060-1105
    Krakow, 31503, Poland
  • Teva Investigational Site 060-1102
    Poznan, 60-693, Poland
  • Teva Investigational Site 060-1106
    Torun, 87-100, Poland
  • Teva Investigational Site 060-1103
    Warsaw, 02-793, Poland
  • Teva Investigational Site 060-2003
    Dnipropetrovsk, 49101, Ukraine
  • Teva Investigational Site 060-2001
    Kharkiv, 61068, Ukraine
  • Teva Investigational Site 060-2002
    Kharkiv, 61153, Ukraine
  • Teva Investigational Site 060-2007
    Kiev, 4080, Ukraine
  • Teva Investigational Site 060-2005
    Kyiv, 4209, Ukraine
  • Teva Investigational Site 060-2006
    Vinnytsia, 21005, Ukraine
09

References and documents

Publications

  • Coffey B, Jankovic J, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA, Stamler DA, Wieman M, Savola JM, Gordon MF, Alexander JK, Barkay H, Harary E. Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open. 2021 Oct 1;4(10):e2129397. doi: 10.1001/jamanetworkopen.2021.29397. PubMed 34661664 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Dec 2019, 18 months.

Results were first posted in Jun 2020, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2018
First posted
Jun 27, 2018
StartActual
May 31, 2018
Primary completionActual
Dec 9, 2019
CompletionActual
Dec 9, 2019
Results first posted
Jun 9, 2020
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03571256
Collaborators
Nuvelution TS Pharma, Inc.
Responsible party
Sponsor
First posted
Jun 27, 2018
Start date
May 31, 2018
Primary completion
Dec 9, 2019
Completion
Dec 9, 2019
Results posted
Jun 9, 2020
Last update
Nov 9, 2021

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion